Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.
MINIMAL Requirements: Google Chrome 24+, Mozilla Firefox 20+, Internet Explorer 11, Opera 15–18, Apple Safari 7, SeaMonkey 2.15-2.23
ESMO welcomes the adoption of the Resolution on Cancer prevention and control in the context of an integrated approach during the 70th World Health Assembly (WHA), May 22 to 31 in Geneva, Switzerland
A late breaking subanalysis of the phase III CONVERT trial to be presented at the European Lung Cancer Conference (ELCC) shows that white blood cell boosting drugs are safe during concurrent chemo-radiotherapy of small cell lung cancer (SCLC)
White blood cell counts can predict whether or not lung cancer patients will benefit from immunotherapy, according to research to be presented at the European Lung Cancer Conference
The findings pave the way for certain patients to continue treatment if the disease is not progressing according to new, more specific, criteria
Osimertinib improves cancer-related symptoms in patients with advanced lung cancer, according to an analysis of patient-reported outcomes from the AURA3 phase III clinical trial to be presented at ELCC
Patients with advanced non-small-cell lung cancer (NSCLC) who require salvage chemotherapy are 30% more likely to achieve a partial response if they have been pre-treated with a PD-1/PD-L1 checkpoint inhibitor compared to those who have not
Research to be presented at the European Lung Cancer Conference in Geneva, Switzerland on Saturday
Analysis of the drugs that were approved for use by the NHS Cancer Drugs Fund in England has shown that the fund was not good value for patients and society and may have resulted in patients suffering unnecessarily from toxic side effects of the drugs.
Lung cancer patients treated with PD-1/PD-L1 checkpoint inhibitors may be at increased risk of adverse events after receiving the seasonal influenza vaccination, according to the first study measuring this effect
ESMO and IASLC have announced that the 2017 Heine H. Hansen (HHH) Award will be given to Rafal Dziadziuszko, a global leader in clinical thoracic oncology
ESMO and IASLC are pleased to invite journalists to a media brief taking place at the beginning of the European Lung Cancer Conference (ELCC) in the Palexpo Centre in Geneva, on Friday 5 May 2017, from 12:00 to 12:45 CEST
Around 2,000 delegates from across Europe and worldwide will learn about the latest practice-changing science in the field of thoracic oncology at the seventh European Lung Cancer Conference (ELCC) in Geneva, Switzerland, from 5 to 8 May 2017
This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.
For more detailed information on the cookies we use, please check our Privacy Policy.
Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.
